9.80 0.38 (4.03%)

New 52W Low in past week

7,489 XNAS Volume

XNAS 19 Mar, 2025 10:36 AM (EDT)



Insider Trading disclosures for Aardvark Therapeutics Inc.

The latest disclosure was made by Tien-Li Lee in Aardvark Therapeutics Inc. where a trade of 350,002 Series A Convertible Preferred Stock done was reported to US exchanges on Feb. 14, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Tien-Li Lee Director, Chief Executive Officer, Ten Percent Owner 14 Feb 2025 350,002 0 - - Series A Convertible Preferred Stock
Tien-Li Lee Director, Chief Executive Officer, Ten Percent Owner 14 Feb 2025 41,303 1,479,633 - - Common Stock
Tien-Li Lee Director, Chief Executive Officer, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 14 Feb 2025 16,542 1,496,175 - 16 264,672 Common Stock
Jeffrey Chi Director 14 Feb 2025 133,364 133,364 - - Common Stock
Jeffrey Chi Director 14 Feb 2025 1,130,135 0 - - Series C Convertible Preferred Stock
Nelson Sun Chief Financial Officer Purchase of securities on an exchange or from another person at price $ 16.00 per share. 14 Feb 2025 10,000 99,484 - 16 160,000 Common Stock
Nelson Sun Chief Financial Officer 14 Feb 2025 59,332 0 - - Series C Convertible Preferred Stock
Nelson Sun Chief Financial Officer 14 Feb 2025 7,001 89,484 - - Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures